摘要
目的探讨长链非编码RNA(lncRNA)FOXD2-AS1的在食管癌组织中的表达及临床意义.方法检测46例食管癌组织及40例癌旁组织中lncRNA FOXD2-AS1的表达,分析FOXD2-AS1表达与食管癌患者临床相关参数的关系.构建FOXD2-AS1小干扰RNA(siRNA),将siRNA转染到食管癌细胞TE-13中,检测细胞增殖、侵袭、迁移能力.结果食管癌组织中的FOXD2-AS1高表达率高于癌旁组织(65.2%vs.32.5%)(P<0.05).FOXD2-AS1高表达与淋巴结转移、TNM分期和浸润深度有关(P<0.05).MTT实验显示,第6、8天,FOXD2-AS1干扰后细胞增殖能力降低(P<0.05).克隆形成实验显示,FOXD2-AS1干扰后增殖细胞数量为(213±11)个,少于对照组的(382±13)个(P<0.01).FOXD2-AS1干扰后侵袭细胞数量为(100±7)个,少于对照组的(155±20)个(P<0.01).FOXD2-AS1干扰后穿出小室膜部的细胞数量为(80±18)个,少于对照组的(115±15)个(P<0.01).结论LncRNA FOXD2-AS1在食管癌组织中呈现高表达,在肿瘤细胞增殖、侵袭和迁移等方面起重要作用.
Objective To investigate the expression and clinical significance of long noncoding RNA (lncRNA)FOXD2-AS1in esophageal carcinoma tissues.Methods The expression of lncRNA FOXD2-AS1 was detected in 46 esophageal carcinoma tissues(group A)and 40tumor-adjacent tissues (group B).The relationship of FOXD2-AS1 expression and clinical parameters was analyzed.FOXD2-AS1 small interference RNA was constructed and transfected into esophageal carcinoma cell TE-13.The cell proliferation,invasion and migration were detected.Results The percentage of patients with high expression of FOXD2-AS1 in group A was more than that in group B (65.2% vs.32.5%)(P<0.05).The high expression of FOXD2-AS1 was related to lymph node metastasis,TNM stage and infiltration depth (P<0.05).MTT assay showed that the ability of cell proliferation was decreased after FOXD2-AS1 interference on the 6^th and 8^th day(P<0.05).Clone formation assay showed that the number of cell proliferation was lower after FOXD2-AS1 interference than that in control group (P<0.01).The number of invasive cells was (100±7)pieces after FOXD2-AS1 interference,which was less than(155±20)pieces in control group(P<0.01).The number of cells piercing the ependymal part was(80±18)pieces after FOXD2-AS1interference,which was less than (115±15) pieces in control group(P<0.01).Conclusion LncRNA FOXD2-AS1 is highly expressed in esophageal carcinoma tissues,which play an important role in the proliferation,invasion and migration of tumour cells.
作者
程熙
胡玉利
CHENG Xi;HU Yuli(Community Health Service Center of Jiangning Street,Nanjing 211161,CHINA)
出处
《江苏医药》
CAS
2019年第9期896-898,904,共4页
Jiangsu Medical Journal